Vera Therapeutics, Inc. (NASDAQ:VERA) said on Wednesday that it had completed full enrollment (431 participants) in the ...

Five months later the hematuria cleared. Since that time repeated examinations of the urine have not shown red cells or protein. Glomerulus in Case 5 with a Single Lobule Showing Hypercellularity ...

Clinically, these patients generally have hematuria and proteinuria, perhaps less likely to have nephrotic range proteinuria or nephrotic syndrome, but that can be seen. They generally do have ...

The clinical presentation can vary from asymptomatic, microscopic hematuria to the full-blown acute nephritic syndrome, characterized by red to brown urine, proteinuria (which can reach the ...

which is inflammation of the filtering units of the kidney (glomeruli), can be a cause of microscopic hematuria. It is often followed by hypertension, proteinuria (increased protein in urine), and ...

On track to announce primary endpoint result from ORIGIN 3 trial this quarter (2Q 2025) U.S. FDA BLA submission for accelerated approval planned for 2H 2025 BRISBANE, Calif., April 03, 2025 (GLOBE ...

Vera Therapeutics (VERA) announced that it has completed full enrollment in the pivotal ORIGIN Phase 3 trial of atacicept in patients with IgA ...

ORIGIN 3 follows the positive long-term results from the ORIGIN Phase 2b trial that demonstrated sustained and substantial reductions in Gd-IgA1, hematuria and proteinuria, and showed stabilized ...

Brisbane, California Saturday, April 5, 2025, 15:00 Hrs [IST] ...